CD8A and neoplasm: Shane et al. showed that the phosphorylation status of EZH2 determines its property to maintain anti-tumor immunity in CD8+ T memory precursor cells, and Akt-mediated EZH2 phosphorylation lies a key target for enhancing anti-tumor immunotherapy strategies23.